NASDAQ:LAB Standard BioTools (LAB) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free LAB Stock Alerts $2.44 +0.08 (+3.39%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$2.31▼$2.4550-Day Range$2.25▼$2.9252-Week Range$1.46▼$3.16Volume3.64 million shsAverage Volume2.23 million shsMarket Capitalization$707.89 millionP/E RatioN/ADividend YieldN/APrice Target$3.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Standard BioTools alerts: Email Address Standard BioTools MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside46.9% Upside$3.58 Price TargetShort InterestBearish3.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 3 Articles This WeekInsider TradingAcquiring Shares$642,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.47) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.89 out of 5 starsMedical Sector351st out of 916 stocksAnalytical Instruments Industry10th out of 26 stocks 3.5 Analyst's Opinion Consensus RatingStandard BioTools has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStandard BioTools has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.05% of the float of Standard BioTools has been sold short.Short Interest Ratio / Days to CoverStandard BioTools has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Standard BioTools has recently increased by 10.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStandard BioTools does not currently pay a dividend.Dividend GrowthStandard BioTools does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LAB. Previous Next 2.4 News and Social Media Coverage News SentimentStandard BioTools has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Standard BioTools this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for LAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added Standard BioTools to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Standard BioTools insiders have bought more of their company's stock than they have sold. Specifically, they have bought $642,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders53.10% of the stock of Standard BioTools is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.74% of the stock of Standard BioTools is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Standard BioTools are expected to grow in the coming year, from ($0.47) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Standard BioTools is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Standard BioTools is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Standard BioTools Stock (NASDAQ:LAB)Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Read More LAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LAB Stock News HeadlinesApril 27, 2024 | investing.comStandard BioTools to cut costs with restructuring planApril 26, 2024 | finanznachrichten.deStandard BioTools Inc.: Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable GrowthApril 29, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 25, 2024 | globenewswire.comStandard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable GrowthApril 16, 2024 | msn.comTD Cowen Initiates Coverage of Standard BioTools (LAB) with Buy RecommendationApril 16, 2024 | finance.yahoo.comStandard BioTools Inc. (NASDAQ:LAB): Are Analysts Optimistic?April 8, 2024 | globenewswire.comStandard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue ImagingApril 5, 2024 | investing.comStandard BioTools secures deal with Bristol Myers SquibbApril 29, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 4, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Standard BioTools (LAB)April 3, 2024 | globenewswire.comStandard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine ResearchApril 2, 2024 | finance.yahoo.comIs Now The Time To Look At Buying Standard BioTools Inc. (NASDAQ:LAB)?March 29, 2024 | msn.comNikon, Lunaphore team up for spatial biology servicesMarch 20, 2024 | investing.comStandard BioTools swaps preferred for common stockMarch 19, 2024 | finance.yahoo.comEstimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)March 18, 2024 | msn.comStandard Biotools exchanges all outstanding Series B convertible preferred stock for common stockMarch 18, 2024 | globenewswire.comStandard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common StockMarch 5, 2024 | finance.yahoo.comStandard BioTools Inc. (NASDAQ:LAB) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | seekingalpha.comStandard BioTools Inc. (LAB) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comStandard BioTools Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineFebruary 29, 2024 | finance.yahoo.comQ4 2023 Standard BioTools Inc Earnings CallFebruary 28, 2024 | finance.yahoo.comStandard BioTools Inc (LAB) Reports Growth and Margin Expansion in FY2023 Despite Economic ...February 28, 2024 | globenewswire.comStandard BioTools Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | finance.yahoo.comStandard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen SequencingFebruary 22, 2024 | globenewswire.comStandard BioTools to Participate in Upcoming Investor ConferencesFebruary 22, 2024 | benzinga.comStandard BioTools Stock (NASDAQ:LAB), Short Interest ReportFebruary 18, 2024 | msn.comMedical lab technologist faces 25 urine-tampering chargesSee More Headlines Receive LAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/29/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:LAB CUSIPN/A CIK1162194 Webwww.fluidigm.com Phone(650) 266-6000Fax650-871-7152Employees534Year FoundedN/APrice Target and Rating Average Stock Price Target$3.58 High Stock Price Target$4.00 Low Stock Price Target$3.25 Potential Upside/Downside+46.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,660,000.00 Net Margins-70.21% Pretax Margin-69.78% Return on EquityN/A Return on Assets-14.45% Debt Debt-to-Equity RatioN/A Current Ratio1.45 Quick Ratio1.26 Sales & Book Value Annual Sales$106.34 million Price / Sales6.66 Cash FlowN/A Price / Cash FlowN/A Book Value($1.85) per share Price / Book-1.32Miscellaneous Outstanding Shares290,120,000Free Float136,065,000Market Cap$707.89 million OptionableOptionable Beta1.64 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Michael Egholm Ph.D. (Age 61)President, CEO & Director Comp: $640.34kMr. Hanjoon Kim (Age 53)Chief Operating Officer Comp: $468.05kMr. Jeffrey G. Black (Age 55)Chief Financial Officer Dr. Shane Bowen Ph.D.Chief Technology OfficerMr. Adam Taich (Age 48)Chief Strategy Officer Key CompetitorsCytek BiosciencesNASDAQ:CTKBQuanterixNASDAQ:QTRXEyePoint PharmaceuticalsNASDAQ:EYPTPacific Biosciences of CaliforniaNASDAQ:PACBAdaptive BiotechnologiesNASDAQ:ADPTView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 512,937 shares on 4/24/2024Ownership: 0.199%Sumitomo Mitsui Trust Holdings Inc.Bought 8,853,491 shares on 4/19/2024Ownership: 3.052%Evolution Wealth Advisors LLCBought 12,210 shares on 4/19/2024Ownership: 0.004%Cannon Global Investment Management LLCBought 20,000 shares on 4/17/2024Ownership: 0.007%Schoolcraft Capital LLCBought 74,224 shares on 4/15/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions LAB Stock Analysis - Frequently Asked Questions Should I buy or sell Standard BioTools stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LAB shares. View LAB analyst ratings or view top-rated stocks. What is Standard BioTools' stock price target for 2024? 3 brokers have issued twelve-month price targets for Standard BioTools' stock. Their LAB share price targets range from $3.25 to $4.00. On average, they expect the company's share price to reach $3.58 in the next year. This suggests a possible upside of 46.9% from the stock's current price. View analysts price targets for LAB or view top-rated stocks among Wall Street analysts. How have LAB shares performed in 2024? Standard BioTools' stock was trading at $2.21 at the beginning of the year. Since then, LAB stock has increased by 10.4% and is now trading at $2.44. View the best growth stocks for 2024 here. Are investors shorting Standard BioTools? Standard BioTools saw a increase in short interest in March. As of March 31st, there was short interest totaling 10,230,000 shares, an increase of 10.5% from the March 15th total of 9,260,000 shares. Based on an average daily volume of 2,170,000 shares, the short-interest ratio is presently 4.7 days. Approximately 2.7% of the company's shares are short sold. View Standard BioTools' Short Interest. When is Standard BioTools' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our LAB earnings forecast. How can I listen to Standard BioTools' earnings call? Standard BioTools will be holding an earnings conference call on Wednesday, May 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Standard BioTools' earnings last quarter? Standard BioTools Inc. (NASDAQ:LAB) posted its earnings results on Wednesday, February, 28th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.05. The firm had revenue of $28.19 million for the quarter, compared to the consensus estimate of $28 million. What ETFs hold Standard BioTools' stock? ETFs with the largest weight of Standard BioTools (NASDAQ:LAB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).Invesco Nasdaq Future Gen 200 ETF (QQQS). What guidance has Standard BioTools issued on next quarter's earnings? Standard BioTools issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$205.0 million. Who are Standard BioTools' major shareholders? Standard BioTools' stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (3.05%), Assenagon Asset Management S.A. (0.20%), Schoolcraft Capital LLC (0.03%), Cannon Global Investment Management LLC (0.01%) and Evolution Wealth Advisors LLC (0.00%). Insiders that own company stock include Caligan Partners Lp, Casdin Partners Master Fund, L, Eli Casdin and Jeffrey G Black. View institutional ownership trends. How do I buy shares of Standard BioTools? Shares of LAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LAB) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
